Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126


A Randomized, Placebo-Controlled, Double-Blind, Dose Escalation, Single Dose and Steady State Pharmacokinetics Study of 9cUAB30 in Healthy Volunteers.

Kolesar JM, Andrews S, Green H, Havighurst TC, Wollmer BW, DeShong K, Laux DE, Krontiras H, Muccio DD, Kim K, Grubbs CJ, House MG, Parnes HL, Heckman-Stoddard BM, Bailey HH.

Cancer Prev Res (Phila). 2019 Sep 4. pii: canprevres.0310.2019. doi: 10.1158/1940-6207.CAPR-19-0310. [Epub ahead of print]


Pharmacometabolomic Pathway Response of Effective Anticancer Agents on Different Diets in Rats with Induced Mammary Tumors.

Cao Z, Miller MS, Lubet RA, Grubbs CJ, Beger RD.

Metabolites. 2019 Jul 22;9(7). pii: E149. doi: 10.3390/metabo9070149.


Evaluation of the STAT3 inhibitor GLG‑302 for the prevention of estrogen receptor‑positive and ‑negative mammary cancers.

Shoemaker RH, Fox JT, Juliana MM, Moeinpour FL, Grubbs CJ.

Oncol Rep. 2019 Sep;42(3):1205-1213. doi: 10.3892/or.2019.7219. Epub 2019 Jul 4.


Comparison of Effects of Diet on Mammary Cancer: Efficacy of Various Preventive Agents and Metabolomic Changes of Different Diets and Agents.

Lubet RA, Beger RD, Miller MS, Luster J, Seifried HE, Grubbs CJ.

Cancer Prev Res (Phila). 2018 Dec;11(12):831-840. doi: 10.1158/1940-6207.CAPR-18-0116. Epub 2018 Nov 20.


[Corrigendum] Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models.

Lubet RA, Steele VE, Juliana MM, Bode A, Moeinpour F, Grubbs CJ.

Oncol Rep. 2019 Jan;41(1):718. doi: 10.3892/or.2018.6802. Epub 2018 Oct 17.


Screening of Chemopreventive Agents in Animal Models: Results on Reproducibility, Agents of a Given Class, and Agents Tested During Tumor Progression.

Lubet RA, Steele VE, Shoemaker RH, Grubbs CJ.

Cancer Prev Res (Phila). 2018 Oct;11(10):595-606. doi: 10.1158/1940-6207.CAPR-18-0084. Epub 2018 Jul 25. Review.


A novel retinoid X receptor agonist, UAB30, inhibits rhabdomyosarcoma cells in vitro.

Williams AP, Waters AM, Stewart JE, Atigadda VR, Mroczek-Musulman E, Muccio DD, Grubbs CJ, Beierle EA.

J Surg Res. 2018 Aug;228:54-62. doi: 10.1016/j.jss.2018.02.057. Epub 2018 Mar 26.


The retinoid X receptor agonist, 9-cis UAB30, inhibits cutaneous T-cell lymphoma proliferation through the SKP2-p27kip1 axis.

Chou CF, Hsieh YH, Grubbs CJ, Atigadda VR, Mobley JA, Dummer R, Muccio DD, Eto I, Elmets CA, Garvey WT, Chang PL.

J Dermatol Sci. 2018 Jun;90(3):343-356. doi: 10.1016/j.jdermsci.2018.03.006. Epub 2018 Mar 15.


Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKt inhibitor MK2206 in mammary cancer models.

Lubet RA, Steele VE, Juliana MM, Bode A, Moeinpour F, Grubbs CJ.

Oncol Rep. 2018 Sep;40(3):1545-1553. doi: 10.3892/or.2018.6313. Epub 2018 Mar 14. Erratum in: Oncol Rep. 2019 Jan;41(1):718.


Lack of chemopreventive efficacy of metformin in rodent models of urinary bladder, head and neck, and colon/intestine cancer.

Thompson MD, Lubet RA, Mccormick DL, Clapper ML, Bode AM, Juliana MM, Moeinpour F, Grubbs CJ.

Oncol Lett. 2017 Sep;14(3):3480-3486. doi: 10.3892/ol.2017.6632. Epub 2017 Jul 20.


Translation of a Tissue-Selective Rexinoid, UAB30, to the Clinic for Breast Cancer Prevention.

Muccio DD, Atigadda VR, Brouillette WJ, Bland KI, Krontiras H, Grubbs CJ.

Curr Top Med Chem. 2017;17(6):676-695. Review.


5MeCDDO Blocks Metabolic Activation but not Progression of Breast, Intestine, and Tongue Cancers. Is Antioxidant Response Element a Prevention Target?

Lubet RA, Townsend R, Clapper ML, Juliana MM, Steele VE, McCormick DL, Grubbs CJ.

Cancer Prev Res (Phila). 2016 Jul;9(7):616-23. doi: 10.1158/1940-6207.CAPR-15-0294. Epub 2016 May 5.


Preclinical Evaluation of UAB30 in Pediatric Renal and Hepatic Malignancies.

Waters AM, Stewart JE, Atigadda VR, Mroczek-Musulman E, Muccio DD, Grubbs CJ, Beierle EA.

Mol Cancer Ther. 2016 May;15(5):911-21. doi: 10.1158/1535-7163.MCT-15-0521. Epub 2016 Feb 12.


Conformationally Defined Rexinoids and Their Efficacy in the Prevention of Mammary Cancers.

Atigadda VR, Xia G, Deshpande A, Wu L, Kedishvili N, Smith CD, Krontiras H, Bland KI, Grubbs CJ, Brouillette WJ, Muccio DD.

J Med Chem. 2015 Oct 8;58(19):7763-74. doi: 10.1021/acs.jmedchem.5b00829. Epub 2015 Sep 22.


Preclinical Evaluation of a Novel RXR Agonist for the Treatment of Neuroblastoma.

Waters AM, Stewart JE, Atigadda VR, Mroczek-Musulman E, Muccio DD, Grubbs CJ, Beierle EA.

Mol Cancer Ther. 2015 Jul;14(7):1559-69. doi: 10.1158/1535-7163.MCT-14-1103. Epub 2015 May 5.


Prevention of chemically induced urinary bladder cancers by naproxen: protocols to reduce gastric toxicity in humans do not alter preventive efficacy.

Lubet RA, Scheiman JM, Bode A, White J, Minasian L, Juliana MM, Boring DL, Steele VE, Grubbs CJ.

Cancer Prev Res (Phila). 2015 Apr;8(4):296-302. doi: 10.1158/1940-6207.CAPR-14-0347. Epub 2015 Mar 11.


Lack of effect of metformin on mammary carcinogenesis in nondiabetic rat and mouse models.

Thompson MD, Grubbs CJ, Bode AM, Reid JM, McGovern R, Bernard PS, Stijleman IJ, Green JE, Bennett C, Juliana MM, Moeinpour F, Steele VE, Lubet RA.

Cancer Prev Res (Phila). 2015 Mar;8(3):231-9. doi: 10.1158/1940-6207.CAPR-14-0181-T. Epub 2015 Feb 13.


Methyl substitution of a rexinoid agonist improves potency and reveals site of lipid toxicity.

Atigadda VR, Xia G, Desphande A, Boerma LJ, Lobo-Ruppert S, Grubbs CJ, Smith CD, Brouillette WJ, Muccio DD.

J Med Chem. 2014 Jun 26;57(12):5370-80. doi: 10.1021/jm5004792. Epub 2014 Jun 5.


Methyl-substituted conformationally constrained rexinoid agonists for the retinoid X receptors demonstrate improved efficacy for cancer therapy and prevention.

Desphande A, Xia G, Boerma LJ, Vines KK, Atigadda VR, Lobo-Ruppert S, Grubbs CJ, Moeinpour FL, Smith CD, Christov K, Brouillette WJ, Muccio DD.

Bioorg Med Chem. 2014 Jan 1;22(1):178-85. doi: 10.1016/j.bmc.2013.11.039. Epub 2013 Dec 1.


Preventive effects of NSAIDs, NO-NSAIDs, and NSAIDs plus difluoromethylornithine in a chemically induced urinary bladder cancer model.

Nicastro HL, Grubbs CJ, Margaret Juliana M, Bode AM, Kim MS, Lu Y, You M, Milne GL, Boring D, Steele VE, Lubet RA.

Cancer Prev Res (Phila). 2014 Feb;7(2):246-54. doi: 10.1158/1940-6207.CAPR-13-0164. Epub 2013 Dec 17.


Naproxen induces cell-cycle arrest and apoptosis in human urinary bladder cancer cell lines and chemically induced cancers by targeting PI3K.

Kim MS, Kim JE, Lim DY, Huang Z, Chen H, Langfald A, Lubet RA, Grubbs CJ, Dong Z, Bode AM.

Cancer Prev Res (Phila). 2014 Feb;7(2):236-45. doi: 10.1158/1940-6207.CAPR-13-0288. Epub 2013 Dec 10.


Concordant effects of aromatase inhibitors on gene expression in ER+ Rat and human mammary cancers and modulation of the proteins coded by these genes.

Lu Y, You M, Ghazoui Z, Liu P, Vedell PT, Wen W, Bode AM, Grubbs CJ, Lubet RA.

Cancer Prev Res (Phila). 2013 Nov;6(11):1151-61. doi: 10.1158/1940-6207.CAPR-13-0126. Epub 2013 Sep 25.


Diffusion weighted imaging evaluated the early therapy effect of tamoxifen in an MNU-induced mammary cancer rat model.

Zhai G, Grubbs CJ, Stockard CR, Umphrey HR, Beasley TM, Kim H.

PLoS One. 2013 May 21;8(5):e64445. doi: 10.1371/journal.pone.0064445. Print 2013.


Effect of an extract of Withania somnifera root on estrogen receptor-positive mammary carcinomas.

Khazal KF, Samuel T, Hill DL, Grubbs CJ.

Anticancer Res. 2013 Apr;33(4):1519-23.


Effect of intermittent dosing regimens of erlotinib on methylnitrosourea-induced mammary carcinogenesis.

Lubet RA, Szabo E, Iwata KK, Gill SC, Tucker C, Bode A, Steele VE, Juliana MM, Nicastro HL, Grubbs CJ.

Cancer Prev Res (Phila). 2013 May;6(5):448-54. doi: 10.1158/1940-6207.CAPR-12-0322. Epub 2013 Mar 26.


Effects on gene expression in rat liver after administration of RXR agonists: UAB30, 4-methyl-UAB30, and Targretin (Bexarotene).

Vedell PT, Lu Y, Grubbs CJ, Yin Y, Jiang H, Bland KI, Muccio DD, Cvetkovic D, You M, Lubet R.

Mol Pharmacol. 2013 Mar;83(3):698-708. doi: 10.1124/mol.112.082404. Epub 2013 Jan 4.


The CDK4/6 inhibitor PD0332991 reverses epithelial dysplasia associated with abnormal activation of the cyclin-CDK-Rb pathway.

Cabrera MC, Díaz-Cruz ES, Kallakury BV, Pishvaian MJ, Grubbs CJ, Muccio DD, Furth PA.

Cancer Prev Res (Phila). 2012 Jun;5(6):810-21. doi: 10.1158/1940-6207.CAPR-11-0532-T. Epub 2012 Apr 16.


Chemopreventive efficacy of Targretin in rodent models of urinary bladder, colon/intestine, head and neck and mammary cancers.

Lubet RA, Clapper ML, McCormick DL, Pereira MA, Chang WC, Steele VE, Fischer SM, Juliana MM, Grubbs CJ.

Oncol Rep. 2012 May;27(5):1400-6. doi: 10.3892/or.2012.1673. Epub 2012 Feb 3.


Modulation of gene expression and cell-cycle signaling pathways by the EGFR inhibitor gefitinib (Iressa) in rat urinary bladder cancer.

Lu Y, Liu P, Van den Bergh F, Zellmer V, James M, Wen W, Grubbs CJ, Lubet RA, You M.

Cancer Prev Res (Phila). 2012 Feb;5(2):248-59. doi: 10.1158/1940-6207.CAPR-10-0363. Epub 2011 Oct 7.


Lapatinib, a preventive/therapeutic agent against mammary cancer, suppresses RTK-mediated signaling through multiple signaling pathways.

Li J, Cho YY, Langfald A, Carper A, Lubet RA, Grubbs CJ, Ericson ME, Bode AM.

Cancer Prev Res (Phila). 2011 Aug;4(8):1190-7. doi: 10.1158/1940-6207.CAPR-10-0330. Epub 2011 Jul 26.


Resveratrol derivatives as promising chemopreventive agents with improved potency and selectivity.

Kondratyuk TP, Park EJ, Marler LE, Ahn S, Yuan Y, Choi Y, Yu R, van Breemen RB, Sun B, Hoshino J, Cushman M, Jermihov KC, Mesecar AD, Grubbs CJ, Pezzuto JM.

Mol Nutr Food Res. 2011 Aug;55(8):1249-65. doi: 10.1002/mnfr.201100122. Epub 2011 Jun 29.


Effects of 5,6-benzoflavone, indole-3-carbinol (I3C) and diindolylmethane (DIM) on chemically-induced mammary carcinogenesis: is DIM a substitute for I3C?

Lubet RA, Heckman BM, De Flora SL, Steele VE, Crowell JA, Juliana MM, Grubbs CJ.

Oncol Rep. 2011 Sep;26(3):731-6. doi: 10.3892/or.2011.1316. Epub 2011 May 23.


Efficacy of the EGFr inhibitor Iressa on development of chemically-induced urinary bladder cancers: dose dependency and modulation of biomarkers.

Lubet RA, Lu Y, Bode AM, You M, Verney ZM, Steele VE, Townsend R, Juliana MM, Grubbs CJ.

Oncol Rep. 2011 May;25(5):1389-97. doi: 10.3892/or.2011.1200. Epub 2011 Mar 1.


A pilot, first-in-human, pharmacokinetic study of 9cUAB30 in healthy volunteers.

Kolesar JM, Hoel R, Pomplun M, Havighurst T, Stublaski J, Wollmer B, Krontiras H, Brouillette W, Muccio D, Kim K, Grubbs CJ, Bailey HE.

Cancer Prev Res (Phila). 2010 Dec;3(12):1565-70. doi: 10.1158/1940-6207.CAPR-10-0149.


Cross-species comparison of orthologous gene expression in human bladder cancer and carcinogen-induced rodent models.

Lu Y, Liu P, Wen W, Grubbs CJ, Townsend RR, Malone JP, Lubet RA, You M.

Am J Transl Res. 2010 Sep 20;3(1):8-27.


Parity is associated with an expanded macrophage population in the mammary gland.

Zhao W, Grubbs CJ, Myers RK, Nilsen-Hamilton M.

Int J Oncol. 2010 Nov;37(5):1195-202.


Screening agents for preventive efficacy in a bladder cancer model: study design, end points, and gefitinib and naproxen efficacy.

Lubet RA, Steele VE, Juliana MM, Grubbs CJ.

J Urol. 2010 Apr;183(4):1598-603. doi: 10.1016/j.juro.2009.12.001. Epub 2010 Feb 20.


Chemopreventive efficacy of naproxen and nitric oxide-naproxen in rodent models of colon, urinary bladder, and mammary cancers.

Steele VE, Rao CV, Zhang Y, Patlolla J, Boring D, Kopelovich L, Juliana MM, Grubbs CJ, Lubet RA.

Cancer Prev Res (Phila). 2009 Nov;2(11):951-6. doi: 10.1158/1940-6207.CAPR-09-0080.


Induced expression of drug metabolizing enzymes by preventive agents: role of the antioxidant response element.

Lubet RA, Yao R, Grubbs CJ, You M, Wang Y.

Chem Biol Interact. 2009 Nov 10;182(1):22-8. doi: 10.1016/j.cbi.2009.08.011. Epub 2009 Aug 18.


High Cks1 expression in transgenic and carcinogen-initiated mammary tumors is not always accompanied by reduction in p27Kip1.

Westbrook L, Ramanathan HN, Isayeva T, Mittal AR, Qu Z, Johnson MD, Kern FG, Ponnazhagan S, Grubbs CJ, Thottassery JV.

Int J Oncol. 2009 May;34(5):1425-31.


Prevention of KLF4-mediated tumor initiation and malignant transformation by UAB30 rexinoid.

Jiang W, Deng W, Bailey SK, Nail CD, Frost AR, Brouillette WJ, Muccio DD, Grubbs CJ, Ruppert JM, Lobo-Ruppert SM.

Cancer Biol Ther. 2009 Feb;8(3):289-98. Epub 2009 Feb 21.


Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis.

Lubet RA, Boring D, Steele VE, Ruppert JM, Juliana MM, Grubbs CJ.

Cancer Prev Res (Phila). 2009 Feb;2(2):161-7. doi: 10.1158/1940-6207.CAPR-08-0134.


Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers.

Lubet RA, Fischer SM, Steele VE, Juliana MM, Desmond R, Grubbs CJ.

Int J Cancer. 2008 Nov 15;123(10):2254-9. doi: 10.1002/ijc.23765.


Effect of cranberry juice concentrate on chemically-induced urinary bladder cancers.

Prasain JK, Jones K, Moore R, Barnes S, Leahy M, Roderick R, Juliana MM, Grubbs CJ.

Oncol Rep. 2008 Jun;19(6):1565-70.


Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes.

Lubet RA, Szabo E, Christov K, Bode AM, Ericson ME, Steele VE, Juliana MM, Grubbs CJ.

Mol Cancer Ther. 2008 Apr;7(4):972-9. doi: 10.1158/1535-7163.MCT-07-2141. Epub 2008 Mar 28.


Short-term modulation of cell proliferation and apoptosis and preventive/therapeutic efficacy of various agents in a mammary cancer model.

Christov K, Grubbs CJ, Shilkaitis A, Juliana MM, Lubet RA.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5488-96.


Preventive effects of polyphenon E on urinary bladder and mammary cancers in rats and correlations with serum and urine levels of tea polyphenols.

Lubet RA, Yang CS, Lee MJ, Hara Y, Kapetanovic IM, Crowell JA, Steele VE, Juliana MM, Grubbs CJ.

Mol Cancer Ther. 2007 Jul;6(7):2022-8.


Gene expression profiling of chemically induced rat bladder tumors.

Yao R, Yi Y, Grubbs CJ, Lubet RA, You M.

Neoplasia. 2007 Mar;9(3):207-21.


Effects of the farnesyl transferase inhibitor R115777 (Zarnestra) on mammary carcinogenesis: prevention, therapy, and role of HaRas mutations.

Lubet RA, Christov K, You M, Yao R, Steele VE, End DW, Juliana MM, Grubbs CJ.

Mol Cancer Ther. 2006 Apr;5(4):1073-8.

Supplemental Content

Loading ...
Support Center